Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates

Details

• Alternative Title:
  PLoS Negl Trop Dis
• Personal Author:
  Smith, Darci R. ; Johnston, Sara C. ; Piper, Ashley ; Botto, Miriam ; Donnelly, Ginger ; Shamblin, Joshua ; Albariño, César G. ; Hensley, Lisa E. ; Schmaljohn, Connie ; Nichol, Stuart T. ; Bird, Brian H.
• Description:
  Rift Valley fever virus (RVFV) is an important mosquito-borne veterinary and human pathogen that has caused large outbreaks of severe disease throughout Africa and the Arabian Peninsula. Currently, no licensed vaccine or therapeutics exists to treat this potentially deadly disease. The explosive nature of RVFV outbreaks and the severe consequences of its accidental or intentional introduction into RVFV-free areas provide the impetus for the development of novel vaccine candidates for use in both livestock and humans. Rationally designed vaccine candidates using reverse genetics have been used to develop deletion mutants of two known RVFV virulence factors, the NSs and NSm genes. These recombinant viruses were demonstrated to be protective and immunogenic in rats, mice, and sheep, without producing clinical illness in these animals. Here, we expand upon those findings and evaluate the single deletion mutant (ΔNSs rRVFV) and double deletion mutant (ΔNSs-ΔNSm rRVFV) vaccine candidates in the common marmoset (Callithrix jacchus), a non-human primate (NHP) model resembling severe human RVF disease. We demonstrate that both the ΔNSs and ΔNSs-ΔNSm rRVFV vaccine candidates were found to be safe and immunogenic in the current study. The vaccinated animals received a single dose of vaccine that led to the development of a robust antibody response. No vaccine-induced adverse reactions, signs of clinical illness or infectious virus were detected in the vaccinated marmosets. All vaccinated animals that were subsequently challenged with RVFV were protected against viremia and liver disease. In summary, our results provide the basis for further development of the ΔNSs and ΔNSs-ΔNSm rRVFV as safe and effective human RVFV vaccines for this significant public health threat.
• Subjects:
  Animals Antibodies, Viral Callithrix Disease Models, Animal Drug Evaluation, Preclinical Humans Rift Valley Fever Rift Valley Fever Virus Sequence Deletion Vaccination Vaccines, Attenuated Viral Nonstructural Proteins Viral Vaccines

  More +
• Source:
  PLoS Negl Trop Dis. 12(5).
• Pubmed ID:
  29742102
• Pubmed Central ID:
  PMC5962102
• Document Type:
  Journal Article
• Volume:
  12
• Issue:
  5
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:c0a0db421d67fae32a4bda5f67ed0e5775394de18ba8272487108980d08a3fd3
• Download URL:
  https://stacks.cdc.gov/view/cdc/61212/cdc_61212_DS1.pdf
• File Type:
  [PDF - 1.99 MB ]